The National Institute for Health and Care Excellence (NICE) has issued four Technology Appraisal decisions in September 2026, comprising three positive first recommendations and one negative decision. Decisions… read more.
Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like… read more.
BioMarin Pharmaceutical Inc. announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International… read more.
Immedica announces that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to pegzilarginase for the treatment of arginase 1 deficiency (ARG1-D), a… read more.
New research led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, in collaboration with an international partnership of researchers, has, for the first… read more.
The new drug is a starting point for therapies that treat OA at its source. Osteoarthritis (OA) is a chronic, painful joint disease and a leading cause of… read more.
Neck and back pain could be caused by changes in gene activity that trigger the breakdown of the spine’s natural shock absorbers, new research suggests. Findings from a… read more.
A multi-institutional research team led by Central South University (CSU) and The Chinese University of Hong Kong (CUHK) has unveiled the most comprehensive genomic analysis to date of… read more.
Does informing people about their genetic risk of obesity help them change their habits and lose excess weight? A study, published in the journal Obesity Reviews by scientists including researchers… read more.
New, previously unpublished clinical data was presented today at ISSCR 2026 demonstrating that transplanted human neural progenitor cells survived for at least one year following subretinal transplantation in… read more.
Novo Nordisk Pharma Co., Ltd. (Japan) announced an adaptation to the existing approval for its long-acting human growth hormone analog formulation “Sogrua” (generic name: Somapsitan (genetically modified)). The… read more.
Arrowhead Pharmaceuticals, Inc. announced that the European Commission (EC) has formally granted marketing authorization for Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
